ArticleFrontiers in oncology2025
Global burden of ovarian and uterine cancers attributable to high body-mass index in 204 countries and territories, 1990-2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High body mass index (BMI) is a well-established risk factor for ovarian and uterine cancer. However, the global, regional, and national burden of these cancers attributable to high BMI remains underexplored. This study quantifies the trends and disparities in the burden of ovarian and uterine cancer due to high BMI from 1990 to 2021 using the Global Burden of Disease (GBD) 2021 dataset. Methods: We extracted data from GBD 2021 to estimate the mortality, incidence, and disability-adjusted life years (DALYs) attributable to high BMI for ovarian and uterine cancer across different locations and time periods. We focused on the burden of ovarian and uterine cancers among women aged 20-49. Age-standardized rates (ASRs) were calculated, and temporal trends were analyzed using the estimated annual percentage change (EAPC). Regional and national disparities were assessed using sociodemographic index (SDI) classifications. Forecasts employed the exponential smoothing (ES) and autoregressive integrated moving average (ARIMA) models. Results: Globally, the burden of ovarian and uterine cancer attributable to high BMI increased substantially from 1990 to 2021, with variations across regions and countries. High-income and upper-middle-income regions exhibited the highest ASRs, whereas low-SDI countries showed increasing trends in recent years. The EAPC analysis indicated a growing burden in developing regions, reflecting the rising prevalence of obesity. Age-stratified analysis revealed that middle-aged and older adults bear the highest burden. Conclusions: The global burden of ovarian and uterine cancer attributable to high BMI has increased significantly over the past three decades. Targeted interventions, including obesity prevention and cancer screening, are crucial for mitigating this burden, particularly in emerging high-risk regions. These findings underscore the need for urgent public health strategies to address obesity-related cancer risks worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.